[1] Ferlay J, Shin H R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer,2010,127(12):2893-2917. [2] 叶定伟,张海梁. 中国肾癌诊治现状和发展趋势[J]. 中华泌尿外科杂志,2014,35(6):401-405. [3] Demery M E, Thezenas S, Pouessel D, et al. Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function[J]. Anticancer Drugs,2012,23(2):143-148. [4] 刘卫. 肾癌根治手术后患者生活质量的调查分析[D]. 大连医科大学,2013. [5] Lambea J, Hinojo C, Lainez N, et al. Quality of life and supportive care for patients with metastatic renal cell carcinoma[J]. Cancer Metastasis Rev,2012,31 Suppl 1:S33-S39. [6] Butt Z, Peipert J, Webster K, et al. General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)[J]. Cancer,2013,119(2):429-437. [7] Baum G, Basen-Engquist K, Swartz M C, et al. Comparing PROMIS computer-adaptive tests to the Brief Symptom Inventory in patients with prostate cancer[J]. Qual Life Res,2014,23(7):2031-2035. [8] Salsman J M, Schalet B D, Andrykowski M A, et al. The impact of events scale: a comparison of frequency versus severity approaches to measuring cancer-specific distress[J]. Psychooncology,2015. [9] Ames S C, Parker A S, Crook J E, et al. Quality of life of patients undergoing surgical treatment for newly-diagnosed, clinically localized renal cell carcinoma[J]. J Psychosoc Oncol,2011,29(6):593-605. [10] 蒋鸿涛,王毅,秦国庆. 肾癌根治术后精神障碍临床分析[J]. 中外健康文摘,2011,08(46):467-468. [11] 罗斌,王博,蒋学文. 影响肾癌预后的危险因素分析[J]. 中国实用医药,2011,06(11):36-37. [12] Maclennan S, Imamura M, Lapitan M C, et al. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer[J]. Eur Urol,2012,62(6):1097-1117. [13] Clark P E, Schover L R, Uzzo R G, et al. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue[J]. Urology,2001,57(2):252-256. [14] Xu K Y, Wu S. Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma[J]. Biomark Res,2015,3:5. [15] Mitchell A P, Hirsch B R, Harrison M R, et al. Deferred Systemic Therapy in Patients With Metastatic Renal Cell Carcinoma[J]. Clin Genitourin Cancer,2014. [16] Psutka S P, Kim S P, Gross C P, et al. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization[J]. Urology,2015,85(2):442-450. [17] Motzer R J, Hutson T E, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2009,27(22):3584-3590. [18] 丁震宇. 舒尼替尼治疗肾细胞癌的新进展[J]. 临床肿瘤学杂志,2010,15(5):461-464. [19] Rini B I, Choueiri T K, Elson P, et al. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma[J]. Cancer,2008,113(6):1309-1314. [20] Bukowski R, Cella D, Gondek K, et al. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer[J]. Am J Clin Oncol,2007,30(3):220-227. [21] Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes[J]. Cancer Treat Rev,2009,35(8):733-737. [22] 王青蓝. 索拉非尼靶向治疗晚期肾癌的临床价值分析[J]. 实用药物与临床,2013,16(4):288-290. [23] Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J]. N Engl J Med,2007,356(22):2271-2281. [24] 周爱萍,杜春霞,孙永琨,等. 替西罗莫司治疗转移性肾细胞癌初探[J]. 癌症进展,2012,10(3):301-305. [25] Trask P C, Bushmakin A G, Cappelleri J C, et al. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib[J]. Acta Oncol,2008,47(5):843-851. [26] 付桂英. 肾细胞癌治疗药--阿西替尼的研究进展[J]. 中国临床药理学杂志,2014(4):371-373. |